Literature DB >> 28951364

[Inhibitory effect of giganteaside D on hepatocellular carcinoma Hep 3b cells and the underlying mechanisms].

Shu-Wen Xie1, Yan-Ni Wang, Hui-Yan Luo, Zi-Bin Lu, Lin-Zhong Yu, Jun-Shan Liu.   

Abstract

OBJECTIVE: To investigate the inhibitory effect of giganteaside D (GD) on hepatocellular carcinoma and its molecular mechanisms.
METHODS: The inhibitory effects of GD on Hep 3b cells were determined using MTT assay and colony formation assay. The morphological changes of Hep 3b cells after GD treatment were observed by electron microscopy, and the cell cycle changes was analyzed using flow cytometry. The cell apoptosis and mitochondrial potential collapse in the treated cells were tested with Hoechst staining assay and flow cytometry. The expression levels of Bcl-2, PARP and key proteins in MAPK pathway were detected using Western blotting.
RESULTS: GD showed a significant inhibitory effect on Hep 3b cells with an IC50 value of 16.08 µmol/L at 72 h. Flow cytometric analysis demonstrated that the phases of cell cycle remained unchanged and a sub-G1 peak (from 3.3% to 33.6%) appeared as GD concentration increased. GD-induced apoptosis was further conformed by Hoechst staining assay, and flow cytometry showed increased mitochondrial potential collapse in the cells. Western blotting demonstrated the cleavage of PARP, decrease of Bcl-2 and p-Erk1/2 (Thr202/Tyr204), and activation of p-p38 (Thr180/Tyr182) and p-JNK (Thr183/Tyr185) in GD-treated cells.
CONCLUSIONS: GD has significant inhibitory effect against hepatocellular carcinoma cells in vitro by inducing apoptosis possibly in association with the MAPK signaling pathway.

Entities:  

Year:  2017        PMID: 28951364      PMCID: PMC6765485     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  23 in total

Review 1.  Novel molecular targets for diagnosis and treatment of hepatocellular carcinoma.

Authors:  Lifang Ma; Lijuan Ji; Yongchun Yu; Jiayi Wang
Journal:  Discov Med       Date:  2015-01       Impact factor: 2.970

2.  Giganteaside D induces ROS-mediated apoptosis in human hepatocellular carcinoma cells through the MAPK pathway.

Authors:  Junshan Liu; Xiduan Wei; Yafeng Wu; Yanni Wang; Yuwen Qiu; Junmin Shi; Hongling Zhou; Zibin Lu; Meng Shao; Linzhong Yu; Li Tong
Journal:  Cell Oncol (Dordr)       Date:  2016-03-25       Impact factor: 6.730

3.  Discovery of bufadienolides as a novel class of ClC-3 chloride channel activators with antitumor activities.

Authors:  Junshan Liu; Dongmei Zhang; Yuan Li; Weimin Chen; Zhixiong Ruan; Lijuan Deng; Liwei Wang; Haiyan Tian; Anita Yiu; Chunlin Fan; Hai Luo; Shanwen Liu; Ying Wang; Gaokeng Xiao; Lixin Chen; Wencai Ye
Journal:  J Med Chem       Date:  2013-07-10       Impact factor: 7.446

4.  Patrinia scabiosaefolia extract suppresses proliferation and promotes apoptosis by inhibiting the STAT3 pathway in human multiple myeloma cells.

Authors:  Jun Peng; Youqin Chen; Jiumao Lin; Qunchuan Zhuang; Wei Xu; Zhenfeng Hong; Thomas J Sferra
Journal:  Mol Med Rep       Date:  2011-01-03       Impact factor: 2.952

5.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

Review 6.  Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma.

Authors:  Yangyang Hu; Shengpeng Wang; Xu Wu; Jinming Zhang; Ruie Chen; Meiwan Chen; Yitao Wang
Journal:  J Ethnopharmacol       Date:  2013-08-01       Impact factor: 4.360

Review 7.  Systemic therapies for hepatocellular carcinoma.

Authors:  Shaohua Ge; Dingzhi Huang
Journal:  Drug Discov Ther       Date:  2015-10

8.  Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK.

Authors:  Hayato Nakagawa; Shin Maeda
Journal:  Patholog Res Int       Date:  2012-05-14

9.  Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase.

Authors:  Yu-Min Feng; Chin-Wen Feng; Syue-Yi Chen; Hsiao-Yen Hsieh; Yu-Hsin Chen; Cheng-Da Hsu
Journal:  BMC Cancer       Date:  2015-03-17       Impact factor: 4.430

10.  Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer.

Authors:  Chunmei Wang; Antonio Cigliano; Salvatore Delogu; Julia Armbruster; Frank Dombrowski; Matthias Evert; Xin Chen; Diego F Calvisi
Journal:  Cell Cycle       Date:  2013-06-06       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.